CUDC-101 | Dual HDAC and EGFR inhibitor
NMR (Conforms)
Available Options
| Size : | Price | Quantity | |
|---|---|---|---|
| 5 mg | $70.00 | ||
| 25 mg | $280.00 |
CUDC-101 (1012054-59-9) is a novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2, IC50 = 4.4, 2.4 and 15.7 nM respectively.1 It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors.1,2
References/Citations:
1) Lai et al. (2010), CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potential anticancer activity; Cancer Res., 70 3647
2) Cai et al. (2010), Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer; J. Med. Chem., 53 2000
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
CUDC-101 (1012054-59-9) is a novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2, IC50 = 4.4, 2.4 and 15.7 nM respectively.1 It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors.1,2
References/Citations:
1) Lai et al. (2010), CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potential anticancer activity; Cancer Res., 70 3647
2) Cai et al. (2010), Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer; J. Med. Chem., 53 2000
Related products
-
SAHA | HDAC inhibitor
From $35.00CAS:149647-78-9Catalog Number:10-1067Activity:HDAC inhibitorAlternate Names:VorinostatChemical Name:Suberoylanilide-hydroxamic acidMolecular Weight:264.33Molecular Formula:C14H20N2O3Solubility:Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml).Physical Properties:White solidPurity:98%
NMR (Conforms)Storage Temperature:RTStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 6 months.Shipping Code:RT -
Cantharidin | Phosphatase PP2A inhibitor
From $40.00CAS:56-25-7Catalog Number:10-1013Activity:Phosphatase PP2A inhibitorChemical Name:3α,7α-Dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dioneMolecular Weight:196.2Molecular Formula:C10H12O4Solubility:Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 5 mg/ml).Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 weeks.Shipping Code:RT -
Troglitazone | PPARgamma agonist
From $86.00CAS:97322-87-7Catalog Number:10-1046Activity:PPARγ agonistChemical Name:(±)-5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]-benzyl]-2,4-thiazolidinedioneMolecular Weight:441.55Molecular Formula:C24H27NO5SSolubility:Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 25 mg/ml).Physical Properties:Off-white solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
